Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gains from Sales and Divestitures (2017 - 2023)

Historic Gains from Sales and Divestitures for Aptevo Therapeutics (APVO) over the last 7 years, with Q3 2023 value amounting to $99303.0.

  • Aptevo Therapeutics' Gains from Sales and Divestitures rose 53254.35% to $99303.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $99303.0, marking a year-over-year increase of 53254.35%. This contributed to the annual value of $17903.0 for FY2022, which is 169030.0% up from last year.
  • As of Q3 2023, Aptevo Therapeutics' Gains from Sales and Divestitures stood at $99303.0, which was up 53254.35% from $50525.0 recorded in Q2 2023.
  • Aptevo Therapeutics' 5-year Gains from Sales and Divestitures high stood at $133040.0 for Q2 2019, and its period low was $1000.0 during Q4 2021.
  • For the 5-year period, Aptevo Therapeutics' Gains from Sales and Divestitures averaged around $60719.4, with its median value being $46056.0 (2023).
  • In the last 5 years, Aptevo Therapeutics' Gains from Sales and Divestitures crashed by 9187.09% in 2020 and then skyrocketed by 169030.0% in 2022.
  • Aptevo Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $133040.0 in 2019, then crashed by 91.87% to $10815.0 in 2020, then crashed by 90.75% to $1000.0 in 2021, then soared by 1690.3% to $17903.0 in 2022, then skyrocketed by 454.67% to $99303.0 in 2023.
  • Its Gains from Sales and Divestitures stands at $99303.0 for Q3 2023, versus $50525.0 for Q2 2023 and $46056.0 for Q1 2023.